Latest Cancer immunotherapy Stories
Investment bolsters immediate capital needs for progressing clinical programs SEATTLE, March 10, 2015 /PRNewswire/ -- TapImmune,
Researchers at Northwestern University have announced a cancer-treatment breakthrough based on three decades of work.
SOUTH SAN FRANCISCO, Calif., March 2, 2015 /PRNewswire/ -- CytomX, a biotechnology company developing Probody(TM) therapeutics for the treatment of cancer, today announced the creation of
NEW YORK, Feb.
LAKE FOREST, Calif., Feb. 24, 2015 /PRNewswire/ -- Cryoport, Inc.
Move puts company in ideal position to attract top scientific and medical talent to advance OncoVAX® clinical trial BALTIMORE, Feb.
LOS ANGELES, Feb. 18, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced the appointment of Steven J.
Selective RORgamma agonist product candidates demonstrated activity as single agent therapy NEW YORK and ANN ARBOR, Mich., Feb.
Proceeds will Fund ACTIVE: the Phase IIIb OncoVAX® Trial and Company Expansion FREDERICK, Md., Jan.
- A person in a secondary role, specifically the second most important character (after the protagonist).